NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT04196283 2023-02-27A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaAbbViePhase 1 Completed30 enrolled